CH7057288 is a potent and selective inhibitor of the MDM2-p53 protein-protein interaction, making it a valuable tool in cancer research. It functions by disrupting the binding between MDM2 and the tumor suppressor protein p53, which leads to stabilization and activation of p53 in cancer cells that overexpress MDM2. This activation triggers cell cycle arrest and apoptosis, particularly in tumor cells with wild-type p53. Its primary application is in oncology drug development, especially for cancers where the p53 pathway is intact but suppressed by high levels of MDM2, such as certain sarcomas, leukemias, and solid tumors. CH7057288 is widely used in preclinical studies to evaluate the therapeutic potential of MDM2 inhibition, including combination therapies with chemotherapy, radiation, or targeted agents. Due to its selectivity and potency, it serves as a critical reference compound for designing new MDM2 inhibitors with improved pharmacokinetic and safety profiles.